Sage Therapeutics, Inc. (NASDAQ:SAGE) had its price target reduced by Cowen and Company from $100.00 to $90.00 in a research note published on Tuesday. They currently have an outperform rating on the biopharmaceutical company’s stock.

A number of other brokerages have also recently weighed in on SAGE. Leerink Swann reissued an outperform rating and set a $97.00 target price (up from $90.00) on shares of Sage Therapeutics in a report on Tuesday, June 20th. ValuEngine raised shares of Sage Therapeutics from a sell rating to a hold rating in a report on Friday, June 2nd. Stifel Nicolaus initiated coverage on shares of Sage Therapeutics in a report on Wednesday, August 9th. They issued a buy rating and a $104.00 price objective on the stock. Needham & Company LLC reaffirmed a buy rating and issued a $82.00 price objective on shares of Sage Therapeutics in a report on Tuesday, June 13th. Finally, Canaccord Genuity set a $110.00 price objective on shares of Sage Therapeutics and gave the stock a buy rating in a report on Saturday, August 5th. Four analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of Buy and a consensus price target of $86.77.

Sage Therapeutics (NASDAQ SAGE) traded down 2.21% on Tuesday, reaching $63.42. 606,113 shares of the company’s stock were exchanged. The firm’s market capitalization is $2.37 billion. Sage Therapeutics has a 1-year low of $38.30 and a 1-year high of $90.80. The stock’s 50 day moving average price is $81.85 and its 200 day moving average price is $74.87.

Sage Therapeutics (NASDAQ:SAGE) last issued its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($1.88) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.63) by ($0.25). During the same period in the prior year, the business earned ($1.08) EPS. On average, analysts expect that Sage Therapeutics will post ($7.38) earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Sage Therapeutics, Inc. (SAGE) PT Lowered to $90.00 at Cowen and Company” was published by Daily Political and is the property of of Daily Political. If you are accessing this report on another publication, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this report can be read at https://www.dailypolitical.com/2017/09/15/sage-therapeutics-inc-sage-pt-lowered-to-90-00-at-cowen-and-company.html.

A number of institutional investors have recently added to or reduced their stakes in SAGE. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Sage Therapeutics by 11.1% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,378 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 138 shares during the period. Turner Investments LLC acquired a new position in Sage Therapeutics during the 2nd quarter valued at about $159,000. Dubuque Bank & Trust Co. acquired a new position in Sage Therapeutics during the 2nd quarter valued at about $167,000. Canada Pension Plan Investment Board acquired a new position in Sage Therapeutics during the 2nd quarter valued at about $175,000. Finally, Ameritas Investment Partners Inc. acquired a new position in Sage Therapeutics during the 1st quarter valued at about $180,000.

Sage Therapeutics Company Profile

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.

Analyst Recommendations for Sage Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.